Publication: Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data

A cost-effectiveness analysis co-authored by Ash Bullement, Samuel McMordie, and Anthony Hatswell in collaboration with Swedish Orphan Biovitrum AB (publ) and Bioverativ, a Sanofi Company has been published in PharmacoEconomics – Open.

This analysis builds upon a previous study by Henry et al. to incorporate data concerning joint health outcomes, as well as real-world dosing data.

You can read the open access article by following this link https://www.ncbi.nlm.nih.gov/pubmed/31280415